Abstract
Background To develop and validate a novel, machine learning-derived model for prediction of cardiovascular (CV) mortality risk using office (OBP) and ambulatory blood pressure (ABP), to compare its performance with existing risk scores, and to assess the possibility of predicting ABP phenotypes (i.e. white-coat, ambulatory and masked hypertension) utilizing clinical variables.
Methods Using data from 63,910 patients enrolled in the Spanish ABP monitoring registry, machine-learning approaches (logistic regression, support vector machine, gradient boosted decision trees, and deep neural networks) and stepwise forward feature selection were used for the classification of the data.
Results Over a median follow-up of 4.7 years, 3,808 deaths occurred from which 1,295 were from CV causes. The performance for all tested classifiers increased while adding up to 10 features and converged thereafter. For the prediction of CV mortality, deep neural networks yielded the highest clinical performance. The novel mortality prediction models using OBP (CV-MortalityOBP) and ABP (CV-MortalityABP) outperformed all other risk scores. The area under the curve (AUC) achieved by the novel approach, using OBP variables only, was already significantly higher when compared with the AUC of Framingham score (0.685 vs 0.659, p = 1.97×10−22), the SCORE (0.679 vs 0.613, p = 6.21×10−22), and ASCVD (0.722 vs 0.639, p = 8.03×10−30) risk score. However, prediction of CV mortality with ABP instead of OBP data led to a significant increase in AUC (0.781 vs 0.752, p = 1.73×10−42), accuracy, balanced accuracy and sensitivity. The sensitivity and specificity for detection of ambulatory, masked, and white-coat hypertension ranged between 0.653-0.661 and 0.573-0.651, respectively.
Conclusion We developed a novel risk calculator for CV death using artificial intelligence based on a large cohort of patients included in the Spanish ABP monitoring registry. The receiver operating characteristic curves for CV-MortalityOBP and CV-MortalityABP with deep neural networks models outperformed all other risk metrics. Prediction of CV mortality using ABP data led to a significant increase in performance metrics. The prediction of ambulatory phenotypes using clinical characteristics, including OBP, was limited.
Competing Interest Statement
Felix Mahfoud received speaker honoraria from Medtronic, Recor, Berlin Chemie and Boehringer Ingelheim, and is supported Deutsche Gesellschaft für Kardiologie and Deutsche Forschungsgemeinschaft (SFB TRR219). Michael Böhm reports support from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Servier, Medtronic, Novartis and Vifor. MB is supported by the Deutsche Forschungsgemeinschaft (DFG, TTR SFB- 219, S-01, M-03, M-05). All other authors report no conflict of interest.
Funding Statement
Felix Mahfoud and Michael Böhm received supported by Deutsche Gesellschaft für Kardiologie and Deutsche Forschungsgemeinschaft (SFB TRR219).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset analysed during the current study is not publicly available but is available from the corresponding author on reasonable request.